Pacira BioSciences (PCRX) Receivables (2010 - 2026)

Pacira BioSciences' Receivables history runs 17 years deep, the most recent figure standing at $125.6 million for Q1 2026.

• In Q1 2026, Receivables rose 19.94% year-over-year to $125.6 million; the TTM figure through Mar 2026 stood at $125.6 million (up 19.94% YoY), while the FY2025 annual figure was $124.1 million, up 9.5% from the prior year.
• Receivables was $125.6 million for Q1 2026 at Pacira BioSciences, up from $124.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $125.6 million in Q1 2026 to a low of $91.1 million in Q2 2022.
• Historically, Receivables has averaged $104.4 million across 5 years, with a median of $101.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables surged 87.04% in 2022, then grew 1.2% in 2023.
• A 5-year view of Receivables shows it stood at $98.4 million in 2022, then advanced by 7.28% to $105.6 million in 2023, then increased by 7.34% to $113.3 million in 2024, then rose by 9.5% to $124.1 million in 2025, then increased by 1.26% to $125.6 million in 2026.
• The last three Receivables figures came in at $125.6 million (Q1 2026), $124.1 million (Q4 2025), and $115.3 million (Q3 2025), per Business Quant data.